Safety and transdermal water loss value in patients with non-small cell lung carcinoma who treated with gefitinib

Trial Profile

Safety and transdermal water loss value in patients with non-small cell lung carcinoma who treated with gefitinib

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Carcinoma; Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 07 Apr 2017 New trial record
    • 01 Mar 2017 Results published in the Dermatology and Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top